Published in J Virol on August 06, 2014
Therapeutic genome editing: prospects and challenges. Nat Med (2015) 2.42
Genome-editing Technologies for Gene and Cell Therapy. Mol Ther (2016) 1.41
Applications of CRISPR technologies in research and beyond. Nat Biotechnol (2016) 1.34
Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology (2014) 1.29
Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications. Genome Biol (2015) 1.10
CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape. Mol Ther (2016) 1.06
Expression of CRISPR/Cas single guide RNAs using small tRNA promoters. RNA (2015) 0.98
Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy. Antiviral Res (2015) 0.97
Epigenome engineering in cancer: fairytale or a realistic path to the clinic? Front Oncol (2015) 0.92
CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection. PLoS One (2015) 0.90
Enabling functional genomics with genome engineering. Genome Res (2015) 0.90
Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment. Virology (2015) 0.90
Genome editing and the next generation of antiviral therapy. Hum Genet (2016) 0.88
Genome editing strategies: potential tools for eradicating HIV-1/AIDS. J Neurovirol (2015) 0.87
The CRISPR/Cas9 genome editing methodology as a weapon against human viruses. Discov Med (2015) 0.86
Prime, Shock, and Kill: Priming CD4 T Cells from HIV Patients with a BCL-2 Antagonist before HIV Reactivation Reduces HIV Reservoir Size. J Virol (2016) 0.84
CRISPR/Cas9 and cancer targets: future possibilities and present challenges. Oncotarget (2016) 0.81
CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections. PLoS Pathog (2016) 0.80
Reprogrammed CRISPR-Cas9 targeting the conserved regions of HPV6/11 E7 genes inhibits proliferation and induces apoptosis in E7-transformed keratinocytes. Asian J Androl (2016) 0.80
Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense. Trends Microbiol (2016) 0.79
Recent Progress in Therapeutic Treatments and Screening Strategies for the Prevention and Treatment of HPV-Associated Head and Neck Cancer. Viruses (2015) 0.79
Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic. Methods (2015) 0.78
The potential for tumor suppressor gene therapy in head and neck cancer. Discov Med (2016) 0.77
CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells. Korean J Intern Med (2017) 0.75
Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape. PLoS Pathog (2016) 0.75
A Small Molecule Inhibitor Selectively Induces Apoptosis in Cells Transformed by High Risk Human Papilloma Viruses. PLoS One (2016) 0.75
Human papillomavirus (HPV) insertional mutation as a dynamic & specific tumour biomarker in HPV-associated carcinoma. Indian J Med Res (2015) 0.75
Inhibition of JCPyV infection mediated by targeted viral genome editing using CRISPR/Cas9. Sci Rep (2016) 0.75
CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles. Mol Ther Nucleic Acids (2016) 0.75
Long-distance interaction of the integrated HPV fragment with MYC gene and 8q24.22 region up-regulating the allele-specific MYC expression in HeLa cells. Int J Cancer (2017) 0.75
A Mathematical Model of Cell Cycle Dysregulation Due to Human Papillomavirus Infection. Bull Math Biol (2017) 0.75
TALEN based HPV-E7 editing triggers necrotic cell death in cervical cancer cells. Sci Rep (2017) 0.75
Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 55.53
RNA-guided human genome engineering via Cas9. Science (2013) 48.29
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell (1990) 20.60
Development and applications of CRISPR-Cas9 for genome engineering. Cell (2014) 13.50
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell (2013) 13.37
Genome-scale CRISPR-Cas9 knockout screening in human cells. Science (2013) 12.36
Genetic screens in human cells using the CRISPR-Cas9 system. Science (2013) 10.75
One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell (2013) 7.99
Functional dissection of the HIV-1 Rev trans-activator--derivation of a trans-dominant repressor of Rev function. Cell (1989) 7.46
High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature (2014) 4.95
Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat Methods (2013) 4.61
Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc Natl Acad Sci U S A (2013) 3.53
Mutational analysis of cis elements involved in E2 modulation of human papillomavirus type 16 P97 and type 18 P105 promoters. J Virol (1990) 2.90
Human papillomaviruses. Annu Rev Microbiol (1994) 2.88
CRISPR-Cas systems: Prokaryotes upgrade to adaptive immunity. Mol Cell (2014) 2.87
Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci U S A (2000) 2.84
Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells. EMBO J (1987) 2.56
Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood (2009) 2.46
Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J Virol (2003) 2.17
Functional analysis of E2-mediated repression of the HPV18 P105 promoter. New Biol (1991) 2.02
Rapid induction of senescence in human cervical carcinoma cells. Proc Natl Acad Sci U S A (2000) 1.93
Oncogenic activities of human papillomaviruses. Virus Res (2009) 1.60
Role of the human papillomaviruses in human cancer. Cancer Res (1991) 1.56
RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J Virol (2003) 1.47
Repression of the human papillomavirus E6 gene initiates p53-dependent, telomerase-independent senescence and apoptosis in HeLa cervical carcinoma cells. J Virol (2004) 1.10
The role of human papillomaviruses in oncogenesis. Recent Results Cancer Res (2014) 1.06
Intratumor injection of small interfering RNA-targeting human papillomavirus 18 E6 and E7 successfully inhibits the growth of cervical cancer. Int J Oncol (2006) 0.95
Adeno-associated virus vectors: immunobiology and potential use for immune modulation. Curr Gene Ther (2012) 0.84